Dupixent (dupilumab) is a non-immunosuppressive, fully human monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation — a major contributor to Atopic Dermatitis, Asthma, and Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).
How Is Dupixent Administered?
Two Dupixent dosing strengths are available — 200 mg and 300 mg — each supplied as a pre-filled syringe. After an initial loading dose, Dupixent injection is given subcutaneously every other week. It can be self-administered in a clinic or, for convenience, at home after training by a healthcare professional. Dupixent is commercially available worldwide, including in the US.
The most common Dupixent side effects include injection site reactions, throat pain (oropharyngeal pain), and cold sores in the mouth or on the lips. Additional side effects reported by Atopic Dermatitis patients include eye and eyelid inflammation — redness, swelling, and itching. Despite this, patient Dupixent reviews for Atopic Dermatitis treatment remain largely positive.
Dupixent Drug Profile: Key Facts
- Molecule Brand: Dupixent
- Generic Name: Dupilumab
- Approval Date: US: March 2017 · Europe: September 2017 · Japan: January 2018
- Molecule Type: Monoclonal Antibody
- Developer: Regeneron Pharmaceuticals
- Marketing Partner: Sanofi
- Primary Indication: Atopic Dermatitis
- Mechanism of Action: Interleukin-4 receptor alpha antagonist
- Route of Administration: Subcutaneous
- Formulation & Dosing: Pediatric — every 2 weeks (200 mg) or 4 weeks (300 mg), weight-based, after a loading dose. Adults — 600 mg initial dose (two 300 mg injections), then 300 mg every other week
- Patent Expiration: US: 2027
The Dupixent manufacturer, Regeneron, developed the drug using its proprietary VelocImmune technology — a genetically engineered mouse platform with a humanized immune system that produces optimized, fully human antibodies.
Regulatory Approvals & Global Reach
Dupixent has been approved for adolescents and adults with moderate-to-severe Atopic Dermatitis in numerous countries, including the US, where it is also approved for children with the condition. Beyond Atopic Dermatitis, Dupixent indications extend to Asthma and Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).
Dupixent is currently approved in over 60 countries. Regeneron and Sanofi have jointly developed dupilumab under a global collaboration agreement since January 2018, and more than 190,000 patients have been treated globally to date.
In 2021, the total prevalent population of Atopic Dermatitis exceeded 65 million across the 7MM (seven major markets), and rising prevalence is expected to keep fueling market growth. Per the DelveInsight Atopic Dermatitis Market Report, the Atopic Dermatitis market size stood at USD 15,026 million in the 7MM in 2021, with continued growth projected through 2032.
Latest Dupixent Update (2022)
In February 2022, the FDA accepted a supplemental Biologics License Application (sBLA) for Dupixent — granting Priority Review — as an add-on maintenance treatment for children aged 6 months to 5 years with moderate-to-severe Atopic Dermatitis not adequately controlled by topical prescription therapies. Dupixent remains the only biologic medicine approved for patients aged 6 years and older in this indication. The FDA decision was expected by June 9, 2022, based on pivotal Phase 3 data combining Dupixent with standard-of-care topical corticosteroids (TCS).
Timeline of Key Milestones
- May 2020: FDA approved Dupixent for children aged 6–11 with moderate-to-severe Atopic Dermatitis uncontrolled by topical therapies.
- June 2020: FDA approved a Dupixent 300 mg pre-filled pen, enabling more convenient at-home administration for patients 12+ across all approved indications.
- November 2020: The European Commission extended Dupixent’s marketing authorization to children aged 6–11 with severe Atopic Dermatitis eligible for systemic therapy.
Prior to dupilumab’s approval, systemic corticosteroids were the only FDA-approved systemic treatment for Atopic Dermatitis in the US — but they aren’t recommended for long-term use. Today, dupilumab first-line systemic treatment for moderate-to-severe Atopic Dermatitis.
Clinical Efficacy and Market Value
Clinical trial results show that roughly three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease severity. However, the therapy carries a high price tag — around USD 15,000 per syringe — which is why physicians often trial cheaper options before moving to Dupixent.
DelveInsight projects Dupixent to reach peak sales of approximately USD 4.5 billion in the United States by 2026.
Atopic Dermatitis Market Analysis and Dupixent’s Position
Dupixent blockbuster drug: in 2020 alone, it generated EUR 3.5 billion (~USD 4.2 billion) for Sanofi, driven by strong demand among adult and adolescent Atopic Dermatitis patients, rapid uptake in children aged 6–11, and continued growth in Asthma and CRSwNP. By the end of 2020, Dupixent was available in 47 countries, treating approximately 230,000 patients.
The Competitive Landscape
United States: Alongside Dupixent, the US Atopic Dermatitis treatment market includes Eucrisa (Crisaborole 2%), Cibinquo, Rinvoq, Adbry (tralokinumab), and Opzelura cream. Eucrisa, a phosphodiesterase 4 inhibitor for mild-to-moderate Atopic Dermatitis, was first approved in December 2016 with a label expansion in March 2020. Incyte’s Opzelura (ruxolitinib) Cream, approved in September 2021, is the first and only topical JAK inhibitor approved for Atopic Dermatitis in the US.
EU5: The market includes Dupixent, Staquis (Crisaborole 2%), Olumiant (Baricitinib), Rinvoq, and Adtralza (tralokinumab). Cibinqo (abrocitinib) was approved in September 2021 by the UK’s MHRA and the EMA for moderate-to-severe Atopic Dermatitis in adults and adolescents.
Japan: The market features Dupixent, Corectim Ointment (0.5% and 0.25%), Difamilast, and Olumiant (Baricitinib). Cibinqo (abrocitinib), an oral once-daily JAK1 inhibitor, was approved in September 2021 for patients aged 12 and older with an inadequate response to existing therapies — expanding treatment options in a historically limited market.
The Road Ahead for Atopic Dermatitis Treatment
While managing atopic itch remains challenging, recent advancements have expanded options from topical agents to advanced systemic therapies like Dupixent. With promising treatments still in the pipeline, the outlook for improving both Atopic Dermatitis symptoms and overall patient quality of life across the 7MM continues to strengthen.
